Brian Walker

What is the International Myeloma Working Group (IMWG)? The IMWG was founded in 2001 by the late Dr. Brian Durie @IMFmyeloma The IMWG has over 325 experts from around the world. You can find all of the members on IMWG.org We work collaboratively to develop diagnostic, prognostic, and response criteria that are the foundation for clinical trials and used by regulatory agencies to adjudicate new drugs and products. We also issue guidelines for clinical practice, and lead several international research projects. The IMWG is unique; there are few diseases which exhibit this level of collaboration. We are committed to curing myeloma and to our patients. To a person, the IMWG is comprised of experts who work selflessly and without ego for the advancement of myeloma research and care. We also work collaboratively with the larger myeloma community represented by the @Myeloma_Society Many of our members are active on social media. Follow them! @NikhilMunshiMD @SagarLonialMD @mvmateos @NoopurRajeMD @Mohty_EBMT @szusmani @myelomaMD @End_myeloma @RahulBanerjeeMD @GKaurMD @YiLinMDPhD @JoshuaRichterMD @paurotero @SurbhiSidanaMD @MyelomaDrKapoor @UrviShahMD @TomBmt133 @BrunoPaiva_UNAV @thanosdimop @PlasmaCellPete @DrGarethMorgan1 @Rfonsi1 @Leif_Bergsagel @ZanwarSaurabh @IrenemGhobrial @sykristinsson @jmikhaelmd @HadidiSamer @freemanlciaraMD @JanakiramMurali @NBahlis @FrancescoMaura4 @chngwj @MalinHultcrantz @AlGarfall @AjaiChari @MyMKaiser @AjayNookaMD @andrew02114 and many more. Tweeting from a plane so my lost will miss some key people. Please check the IMWG.org website which has all our publications and members.

Dr. Benjamin Diamond (@BenDiamondMD) will present new findings from the ReKInDLE study at #ASH25, presenting a potential path forward for early relapse/refractory #MultipleMyeloma patients. Learn more about our presence: Sylvester.org/ASH25.

Make sure to visit IMS Booth 1817 at #ASH25! We're super excited to share what IMS has planned for 2026!

Further verification of the ability to identify HR myeloma at presentation

Genomic markers associated with high risk of progression of smoldering myeloma in various studies. Amazing slide put together by Dr. Brian Walker.

#Myeloma Paper of the Day: Diagnostic sequencing identifies high-risk markers + resistance mechanisms (Cereblon pathway alterations in 24.3% of IMiD-treated pts, del 4p (CD38) in pts post-anti-CD38, BCMA deletions & mutations pts txd w/ anti-BCMA: pubmed.ncbi.nlm.nih.gov/41092482/. #mmsm

At Sylvester Myeloma Institute, we don’t just imagine a multiple myeloma cure, we are building the path to it. Driven by innovation, excellence and collaboration, our globally recognized scientists and clinicians are advancing the transformative therapies of tomorrow. From pioneering clinical trials and computational advancements to training the next generation of myeloma leaders through our Advanced Clinical and Computational Fellowships and International Scholars Program, Sylvester is where myeloma talent thrives and drives impact to improve patients’ lives. #mmsm Come join our team: loom.ly/ErOv-x4 @DrOlaLandgren

For Rare Disease Day this Friday, we spoke with @DrSarahGooding, a clinician scientist in @Chapman_lab_UK at the MRC WIMM researching multiple myeloma, a currently incurable type of bone marrow cancer that desperately requires friendlier therapies. Watch: youtu.be/-H16Wd443EI

@ASH_hematology Join our trainee Nathan Becker, MS, to learn about multiple myeloma patient derived xenografts. ⏰: 5:30 PM 📍: Hall G-H #ASH24 #ResearchCuresCancer @rabonour1 @sci_bri

Love this

In 2005, Rafat Abonour (@rabonour1), MD, set out to find answers for his patients battling multiple myeloma — and that mission fueled his desire to launch Miles for Myeloma. Since then, this event has raised $8.3 million to support research. Learn more: ow.ly/Aw4n50ToogZ.

#Myeloma Paper of the Day: #MGUS risk stratification models can be applied longitudinally to repeatedly determine & improve individual risk of progression, w/ patients who get upstaged to a high-risk category having increased chance of progression: pubmed.ncbi.nlm.nih.gov/39191769/. #mmsm

So lucky to work with Peter @10000Donors and his family, whose fundraising efforts are making the North East Myeloma Genome project possible! Catch us on BBC North tonight bbc.co.uk/news/articles/… Thank you to everyone involved! @profghjackson & NuTH team, @4130chromo @NU_Cancer

Exciting “FLAGSHIP” study opened at @SylvesterCancer Myeloma Institute in Miami! Collaboration with @BostonGeneCorp for exact molecular sub-typing & personalized treatment strategies #mmsm @IMFmyeloma @theMMRF ⁦@HealthTree⁩ ⁦@LLSusa See here: bostongene.com/news-and-publi…

Blood Cancer Discovery’s new Impact Factor is 11.5. Thank you to our authors, reviewers, and editors! bit.ly/4cpME8I

Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors dlvr.it/T9L8n3

In conclusion👇the new FISH MM risk @MyelomaEurope @IMFmyeloma @MyelomaEurope @RahulBanerjeeMD

NOW OPEN: The MMRF is accepting applications for our 2024 Research Fellows Award Program. Successful applicants will receive up to $150,000 in research funding over two years. For details click/tap on the “Projects and Awards” anchor link on this page: ow.ly/EAyl50RHx2N

Myeloma Paper of the Day, May 17th, suggested by @Myeloma_Doc @Johnson_TravisS @pblaneynyu @DrGarethMorgan1 @suvannasankha @DrM_AbuZaid @rabonour1 @sci_bri oncodaily.com/67280.html #Cancer #MyelomaPaperOfTheDay #OncoDaily #Oncology #Myeloma #CancerResearch

#Myeloma Paper of the Day: Single cell multi-omic ATAC- and RNA-seq dataset links one plasma cell subtype with myeloma progression associated with chromosome 1q alterations, TP53 mutations, and higher expression of PHF19, an epigenetic regulator: pubmed.ncbi.nlm.nih.gov/38755140/.